Eversept Partners LP Purchases Shares of 677,924 Compass Pathways PLC Sponsored ADR $CMPS

Eversept Partners LP acquired a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 677,924 shares of the company’s stock, valued at approximately $3,749,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CMPS. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the 4th quarter valued at $38,000. Parallel Advisors LLC increased its position in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter worth about $41,000. North Star Investment Management Corp. lifted its holdings in Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Compass Pathways during the 4th quarter valued at about $47,000. 46.19% of the stock is owned by institutional investors.

Compass Pathways Price Performance

Shares of CMPS stock opened at $11.27 on Tuesday. Compass Pathways PLC Sponsored ADR has a 1 year low of $3.92 and a 1 year high of $15.40. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $12.52 and its 200-day moving average is $9.06. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -3.58 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Sell-side analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CMPS. Maxim Group boosted their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. BTIG Research raised their price objective on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Friday, July 17th. Finally, Wells Fargo & Company initiated coverage on Compass Pathways in a research report on Monday. They set an “equal weight” rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.